Professor Jang Yoon-hyuk of the National Strategic Technology Specialized Research Institute and the Department of Neurology said, "This study offers a new perspective on adult-onset seizures as an issue of brain health in middle age." He added, "However, since this is an observational study, long-term follow-up studies and randomized clinical trials will be needed in the future to verify the actual preventive effect and its clinical applicability." The findings were published in a recent issue of Neurology, the official journal of the American Academy of Neurology
doi: 10.1016/j.tins.2020.06.002 440 BensonCAWongGTenorioGBakerGBKerrBJ
Mult Scler Perspect Treat Pathog 125138
Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, et al
Rehman, K
In the landscape of weight loss medications, Wegovy stands out with its active ingredient, semaglutide, and its FDA-approved status for chronic weight management